CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

This trial is studying a CAR-T cell therapy called CLIC-1901 — immune cells that are re-engineered to recognize and destroy cancer cells carrying the CD19 protein — for people with blood cancers that have returned or stopped responding to prior treatment. **You may be eligible if...** - You have CD19-positive blood cancer (such as B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma) that has relapsed or is refractory - You have had at least 2 relapses, relapsed after a bone marrow transplant, or did not achieve remission after standard treatment - You are in adequate health to receive the therapy - You are 18 years or older **You may NOT be eligible if...** - Your cancer does not carry the CD19 protein marker - You have active, uncontrolled infections - You have had severe reactions to CAR-T therapy before - You have uncontrolled autoimmune disease or serious organ problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.